五年前美国曾有人就今后十年新抗生素的发展趋势对150名高等院校、学术团体从事抗生素科研工作的领导者进行过一次调查,当时多数人预言,在新抗生素研究方面最有发展前途的是目前临床应用的抗生素的结构改造,其次是全新抗生素的发现,再次是全合成抗感染药物的发现;在已有抗生素结构改造方面占首位的是头孢菌素类,其次是青霉素类,再次是利福霉素类和氨基糖苷类。近几年在头孢菌素领域中取得的进展证实这一预言是完全正确的。根据笔者过去对国外专利文献的详细调查,1973～1975年世界上至少有123个公司、厂或研究所从事β-内酰胺抗生素的研究工作,三年总共发的专利件数(包括多国申请在内)约1800件,其 Five years ago, some people in the United States conducted a survey on the trend of new antibiotics in the next ten years to 150 leaders engaged in scientific research on antibiotics in institutions of higher learning and academic organizations when most predicted that they will have the most promising future in new antibiotic research Is currently the structural modification of antibiotics used clinically, followed by the discovery of new antibiotics, and once again the discovery of fully synthetic anti-infective drugs; cephalosporins, followed by penicillins, again in structural modification of existing antibiotics Rifamycins and aminoglycosides. The progress made in the cephalosporin field in recent years confirms that this prediction is entirely correct. According to the author’s detailed investigation of foreign patent documents in the past, from 1973 to 1975, at least 123 companies, factories or research institutes engaged in the research of β-lactam antibiotics, the total number of patents issued in three years (including multinational applications About 1800 pieces of it